corporations, as well as a variety of different industries including apparel and
consumer products. She is the recipient of ... Akamai Technologies Inc. et al v.
Limelight ... Bayer Schering Pharma AG v. Lupin Ltd., et al. ... DeWolfe v.
Jun 17, 2009 ... Rivaroxaban versus placebo in patients with acute coronary ... Turpie AG,
Verheugt F, Ardissino D, Atar D, Aylward P, Bassand JP, ... Beauloye C,
Janssens L, Van Mieghem W, De Wolf L, Sinnaeve P, .... FUNDING: Johnson &
Johnson Pharmaceutical Research & Development and Bayer Healthcare AG.
Philips Electronics North America Corporation, et al., United States Court of ... 10-
1018, November 21, 2011; Paul B. Dewolfe, Jr., v. ... Becton, Dickinson and
Company, and Nova Biomedical Corporation and Bayer Healthcare LLC, U.S.
www.courts.state.md.us/coappeals/highlightedcases/richmond/Brief of Appellees.pdf
Attachment 10: Colbert, Douglas L., et a1., “Do Attorneys Really .... Alabama, 1 v
... DeWolfe V. Richmond, ... 41. Exxon Mobil Corp. V. Ford,. 433 Md. 426 .
Apr 2, 2004 ... Cardiovascular Research, Pharma Research, Bayer HealthCare AG, ...
carboxyltransferase reaction of this enzyme with a competitive inhibition pattern
versus malonyl- ..... synthesis was evaluated by HPLC similar to Hosokawa et al.
(44). ..... C., Berry, V., DeWolf, W. E., Jr., Keller, P. M., Polizzi, B. J., Qiu, X., ...
Jun 17, 2009 ... The risk of clinically significant bleeding with rivaroxaban versus placebo
increased in .... either placebo or rivaroxaban (Bayer Healthcare AG, Leverkusen,
Germany) given once ..... L Janssens, W Van Mieghem, L De Wolf, P Sinnaeve, P
Materne, P Vranckx, .... 3Wallentin, L, Wilcox, RG, Weaver, WD et al.
Mar 2, 2016 ... seed development and endosperm cellularization (Tiwari et al., 2008; Gerald et
al., ...... Nguyen LSL, De Wolf J, Mironov V, Peerbolte R, Beemster GTS, Inzé D, et
al ... Cavrak V V., Lettner N, Jamge S, Kosarewicz A, Bayer LM, ...
p=0.0370 vs HCV-positive recipients with all other genetic combinations). .....
Catherine T. Frenette - Speaking and Teaching: Bayer, Salix, Gilead; Stock.
Shareholder: ..... Goldberg, Zakiyah Kadry, Reena Salgia, Andre M. De Wolf,
David C. Mulligan,. Steven M. ..... were determined by validated algorithm (
Kaplan DE, et al.
Aug 31, 2015 ... Citation: Michel A, Downey P, Van Damme X, De Wolf C, Schwarting R, .... They
were subsequently anesthetized with ketamine (Ceva, 75 mg/kg) and xylazine (
Bayer, ..... and benserazide versus L-Dopa alone), we monitored the unilateral
..... Addy C, Assaid C, Hreniuk D, Stroh M, Xu Y, Herring WJ, et al.
Feb 4, 2015 ... ... to the level of each mRNA in sham (comparisons versus MCT + saline or AAV1
.βGal: **P .... Three days later, virus were purified and quantified as described by
Kohlbrenner et al. .... Borst, P, de Wolf, C and van de Wetering, K (2007). .... This
study was funded through a grant-in-aid from Bayer Healthcare ...